Esperion Therapeutics’ (ESPR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Wednesday,Benzinga reports. The brokerage currently has a $16.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on ESPR. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC dropped their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th.

Esperion Therapeutics Trading Down 1.2 %

NASDAQ ESPR opened at $2.54 on Wednesday. The firm has a market capitalization of $500.48 million, a P/E ratio of -3.97 and a beta of 0.96. The firm’s fifty day moving average price is $2.08 and its two-hundred day moving average price is $2.16. Esperion Therapeutics has a 1 year low of $1.16 and a 1 year high of $3.40.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the company. Capital Advisors Wealth Management LLC lifted its holdings in Esperion Therapeutics by 22.9% during the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 5,000 shares during the last quarter. Boomfish Wealth Group LLC lifted its holdings in shares of Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares in the last quarter. Summit Financial LLC boosted its position in shares of Esperion Therapeutics by 26.4% in the second quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 6,823 shares during the period. National Bank of Canada FI grew its stake in shares of Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,225 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Esperion Therapeutics by 45.3% in the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 11,658 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.